Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-10-2014 | Original Article

Extrastriatal binding of [¹²³I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls

Authors: Walter Koch, Marcus Unterrainer, Guoming Xiong, Peter Bartenstein, Markus Diemling, Andrea Varrone, John C. Dickson, Livia Tossici-Bolt, Terez Sera, Susanne Asenbaum, Jan Booij, Ozlem L. Kapucu, Andreas Kluge, Morten Ziebell, Jacques Darcourt, Flavio Nobili, Marco Pagani, Swen Hesse, Thierry Vander Borght, Koen Van Laere, Klaus Tatsch, Christian la Fougère

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 10/2014

Abstract

Purpose

Apart from binding to the dopamine transporter (DAT), [¹²³I]FP-CIT shows moderate affinity for the serotonin transporter (SERT), allowing imaging of both monoamine transporters in a single imaging session in different brain areas. The aim of this study was to systematically evaluate extrastriatal binding (predominantly due to SERT) and its age and gender dependencies in a large cohort of healthy controls.

Methods

SPECT data from 103 healthy controls with well-defined criteria of normality acquired at 13 different imaging centres were analysed for extrastriatal binding using volumes of interest analysis for the thalamus and the pons. Data were examined for gender and age effects as well as for potential influence of striatal DAT radiotracer binding.

Results

Thalamic binding was significantly higher than pons binding. Partial correlations showed an influence of putaminal DAT binding on measured binding in the thalamus but not on the pons. Data showed high interindividual variation in extrastriatal binding. Significant gender effects with 31 % higher binding in women than in men were observed in the thalamus, but not in the pons. An age dependency with a decline per decade (±standard error) of 8.2 ± 1.3 % for the thalamus and 6.8 ± 2.9 % for the pons was shown.

Conclusion

The potential to evaluate extrastriatal predominant SERT binding in addition to the striatal DAT in a single imaging session was shown using a large database of [¹²³I]FP-CIT scans in healthy controls. For both the thalamus and the pons, an age-related decline in radiotracer binding was observed. Gender effects were demonstrated for binding in the thalamus only. As a potential clinical application, the data could be used as a reference to estimate SERT occupancy in addition to nigrostriatal integrity when using [¹²³I]FP-CIT for DAT imaging in patients treated with selective serotonin reuptake inhibitors.

Booij J, Speelman JD, Horstink MW, Wolters EC. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med. 2001;28:266–72.PubMedCrossRef

Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord. 2000;15:503–10.PubMedCrossRef

Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T, Kapucu OL, et al. EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37:443–50. doi:10.1007/s00259-009-1267-x.PubMedCrossRef

Walker Z, Cummings JL. [123I]N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl)nortropane single-photon emission computed tomography brain imaging in the diagnosis of dementia with Lewy bodies. Alzheimers Dement. 2012;8:74–83. doi:10.1016/j.jalz.2011.08.003.PubMedCrossRef

Abi-Dargham A, Gandelman MS, DeErausquin GA, Zea-Ponce Y, Zoghbi SS, Baldwin RM, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. J Nucl Med. 1996;37:1129–33.PubMed

Hall H, Halldin C, Guilloteau D, Chalon S, Emond P, Besnard J, et al. Visualization of the dopamine transporter in the human brain postmortem with the new selective ligand [125I]PE2I. Neuroimage. 1999;9:108–16.PubMedCrossRef

Madras BK, Gracz LM, Fahey MA, Elmaleh D, Meltzer PC, Liang AY, et al. Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain. Synapse. 1998;29:116–27. doi:10.1002/(SICI)1098-2396(199806)29:2<116::AID-SYN3>3.0.CO;2-A.PubMedCrossRef

Varnas K, Halldin C, Hall H. Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum Brain Mapp. 2004;22:246–60. doi:10.1002/hbm.20035.PubMedCrossRef

Staley JK, Basile M, Flynn DD, Mash DC. Visualizing dopamine and serotonin transporters in the human brain with the potent cocaine analogue [125I]RTI-55: in vitro binding and autoradiographic characterization. J Neurochem. 1994;62:549–56.PubMedCrossRef

10.

Ziebell M, Holm-Hansen S, Thomsen G, Wagner A, Jensen P, Pinborg LH, et al. Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I. J Nucl Med. 2010;51:1885–91. doi:10.2967/jnumed.110.078337.PubMedCrossRef

11.

Booij J, de Jong J, de Bruin K, Knol R, de Win MM, van Eck-Smit BL. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. J Nucl Med. 2007;48:359–66.PubMed

12.

Borgers AJ, Alkemade A, Van de Giessen EM, Drent ML, Booij J, Bisschop PH, et al. Imaging of serotonin transporters with [123I]FP-CIT SPECT in the human hypothalamus. EJNMMI Res. 2013;3:34. doi:10.1186/2191-219X-3-34.PubMedCentralPubMedCrossRef

13.

Koopman KE, la Fleur SE, Fliers E, Serlie MJ, Booij J. Assessing the optimal time point for the measurement of extrastriatal serotonin transporter binding with 123I-FP-CIT SPECT in healthy, male subjects. J Nucl Med. 2012;53:1087–90. doi:10.2967/jnumed.111.102277.PubMedCrossRef

14.

Hesse S, Meyer PM, Strecker K, Barthel H, Wegner F, Oehlwein C, et al. Monoamine transporter availability in Parkinson's disease patients with or without depression. Eur J Nucl Med Mol Imaging. 2009;36:428–35. doi:10.1007/s00259-008-0979-7.PubMedCrossRef

15.

Roselli F, Pisciotta NM, Pennelli M, Aniello MS, Gigante A, De Caro MF, et al. Midbrain SERT in degenerative parkinsonisms: a 123I-FP-CIT SPECT study. Mov Disord. 2010;25:1853–9. doi:10.1002/mds.23179.PubMedCrossRef

16.

Booij J, Hemelaar TG, Speelman JD, de Bruin K, Janssen AG, van Royen EA. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT. J Nucl Med. 1999;40:753–61.PubMed

17.

Rocha FL, Murad MG, Stumpf BP, Hara C, Fuzikawa C. Antidepressants for depression in Parkinson's disease: systematic review and meta-analysis. J Psychopharmacol. 2013;27:417–23. doi:10.1177/0269881113478282.PubMedCrossRef

18.

Kugaya A, Sanacora G, Staley JK, Malison RT, Bozkurt A, Khan S, et al. Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biol Psychiatry. 2004;56:497–502. doi:10.1016/j.biopsych.2004.07.001.PubMedCrossRef

19.

Lanzenberger R, Kranz GS, Haeusler D, Akimova E, Savli M, Hahn A, et al. Prediction of SSRI treatment response in major depression based on serotonin transporter interplay between median raphe nucleus and projection areas. Neuroimage. 2012;63:874–81. doi:10.1016/j.neuroimage.2012.07.023.PubMedCrossRef

20.

Dahlstrom M, Ahonen A, Ebeling H, Torniainen P, Heikkila J, Moilanen I. Elevated hypothalamic/midbrain serotonin (monoamine) transporter availability in depressive drug-naive children and adolescents. Mol Psychiatry. 2000;5:514–22.PubMedCrossRef

21.

Heinz A, Ragan P, Jones DW, Hommer D, Williams W, Knable MB, et al. Reduced central serotonin transporters in alcoholism. Am J Psychiatry. 1998;155:1544–9.PubMed

22.

Hesse S, Barthel H, Murai T, Muller U, Muller D, Seese A, et al. Is correction for age necessary in neuroimaging studies of the central serotonin transporter? Eur J Nucl Med Mol Imaging. 2003;30:427–30. doi:10.1007/s00259-002-1044-6.PubMedCrossRef

23.

Kuikka JT, Tammela L, Bergstrom KA, Karhunen L, Uusitupa M, Tiihonen J. Effects of ageing on serotonin transporters in healthy females. Eur J Nucl Med. 2001;28:911–3.PubMedCrossRef

24.

Newberg AB, Amsterdam JD, Wintering N, Ploessl K, Swanson RL, Shults J, et al. 123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: a preliminary study. J Nucl Med. 2005;46:973–7.PubMed

25.

Pirker W, Asenbaum S, Hauk M, Kandlhofer S, Tauscher J, Willeit M, et al. Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging. J Nucl Med. 2000;41:36–44.PubMed

26.

Ryding E, Lindstrom M, Bradvik B, Grabowski M, Bosson P, Traskman-Bendz L, et al. A new model for separation between brain dopamine and serotonin transporters in 123I-beta-CIT SPECT measurements: normal values and sex and age dependence. Eur J Nucl Med Mol Imaging. 2004;31:1114–8. doi:10.1007/s00259-004-1489-x.PubMedCrossRef

27.

van Dyck CH, Malison RT, Seibyl JP, Laruelle M, Klumpp H, Zoghbi SS, et al. Age-related decline in central serotonin transporter availability with [(123)I]beta-CIT SPECT. Neurobiol Aging. 2000;21:497–501.PubMedCrossRef

28.

Arranz B, Eriksson A, Mellerup E, Plenge P, Marcusson J. Effect of aging in human cortical pre- and postsynaptic serotonin binding sites. Brain Res. 1993;620:163–6.PubMedCrossRef

29.

Allen SJ, Benton JS, Goodhardt MJ, Haan EA, Sims NR, Smith CC, et al. Biochemical evidence of selective nerve cell changes in the normal ageing human and rat brain. J Neurochem. 1983;41:256–65.PubMedCrossRef

30.

Severson JA, Marcusson JO, Osterburg HH, Finch CE, Winblad B. Elevated density of [3H]imipramine binding in aged human brain. J Neurochem. 1985;45:1382–9.PubMedCrossRef

31.

Marcusson JO, Alafuzoff I, Backstrom IT, Ericson E, Gottfries CG, Winblad B. 5-Hydroxytryptamine-sensitive [3H]imipramine binding of protein nature in the human brain. II. Effect of normal aging and dementia disorders. Brain Res. 1987;425:137–45.PubMedCrossRef

32.

Andersson A, Sundman I, Marcusson J. Age stability of human brain 5-HT terminals studied with [3H]paroxetine binding. Gerontology. 1992;38:127–32.PubMedCrossRef

33.

Derogatis LR, Lipman RS, Covi L. SCL-90: an outpatient psychiatric rating scale – preliminary report. Pychopharmacol Bull. 1973;1:13–28.

34.

Beck AT, Steer RA. Beck depression inventory–manual. San Antonio: The Psychological Association; 1987.

35.

Varrone A, Dickson JC, Tossici-Bolt L, Sera T, Asenbaum S, Booij J, et al. European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging. 2013;40:213–27. doi:10.1007/s00259-012-2276-8.PubMedCrossRef

36.

Dickson JC, Tossici-Bolt L, Sera T, de Nijs R, Booij J, Bagnara MC, et al. Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European 123I-FP-CIT SPECT database. Eur J Nucl Med Mol Imaging. 2012;39:188–97. doi:10.1007/s00259-011-1884-z.PubMedCrossRef

37.

Tossici-Bolt L, Dickson JC, Sera T, de Nijs R, Bagnara MC, Jonsson C, et al. Calibration of gamma camera systems for a multicentre European 123I-FP-CIT SPECT normal database. Eur J Nucl Med Mol Imaging. 2011;38:1529–40. doi:10.1007/s00259-011-1801-5.PubMedCrossRef

38.

Chang L. A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci. 1978;21:638–43.CrossRef

39.

Willowson K, Bailey D, Schembri G, Baldock C. CT-based quantitative SPECT for the radionuclide 201Tl: experimental validation and a standardized uptake value for brain tumour patients. Cancer Imaging. 2012;12:31–40.PubMedCentralPubMedCrossRef

40.

Sohlberg A, Watabe H, Iida H. Acceleration of Monte Carlo-based scatter compensation for cardiac SPECT. Phys Med Biol. 2008;53:N277–85. doi:10.1088/0031-9155/53/14/N02.PubMedCrossRef

41.

Sohlberg A, Watabe H, Iida H. Optimal collimator design for cardiac SPECT when resolution recovery is applied in statistical reconstruction. J Nucl Med. 2007;48 Suppl 2:721P.

42.

Collins DL, Neelin P, Peters TM, Evans AC. Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J Comput Assist Tomogr. 1994;18:192–205.PubMedCrossRef

43.

Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273–89. doi:10.1006/nimg.2001.0978.PubMedCrossRef

44.

Laruelle M, Slifstein M, Huang Y. Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. Mol Imaging Biol. 2003;5:363–75.PubMedCrossRef

45.

Backstrom I, Bergstrom M, Marcusson J. High affinity [3H]paroxetine binding to serotonin uptake sites in human brain tissue. Brain Res. 1989;486:261–8.PubMedCrossRef

46.

De Keyser J, De Backer JP, Ebinger G, Vauquelin G. [3H]GBR 12935 binding to dopamine uptake sites in the human brain. J Neurochem. 1989;53:1400–4.PubMedCrossRef

47.

Kupers R, Frokjaer VG, Erritzoe D, Naert A, Budtz-Joergensen E, Nielsen FA, et al. Serotonin transporter binding in the hypothalamus correlates negatively with tonic heat pain ratings in healthy subjects: a [11C]DASB PET study. Neuroimage. 2011;54:1336–43. doi:10.1016/j.neuroimage.2010.09.010.PubMedCrossRef

48.

Chou YH, Yang BH, Chung MY, Chen SP, Su TP, Chen CC, et al. Imaging the serotonin transporter using (123)I-ADAM in the human brain. Psychiatry Res. 2009;172:38–43. doi:10.1016/j.pscychresns.2008.12.006.PubMedCrossRef

49.

van de Giessen E, Booij J. The SPECT tracer [123I]ADAM binds selectively to serotonin transporters: a double-blind, placebo-controlled study in healthy young men. Eur J Nucl Med Mol Imaging. 2010;37:1507–11. doi:10.1007/s00259-010-1424-2.PubMedCentralPubMedCrossRef

50.

Koch W, Schaaff N, Popperl G, Mulert C, Juckel G, Reicherzer M, et al. [I-123]ADAM and SPECT in patients with borderline personality disorder and healthy control subjects. J Psychiatry Neurosci. 2007;32:234–40.PubMedCentralPubMed

51.

Du Y, Tsui BM, Frey EC. Model-based compensation for quantitative 123I brain SPECT imaging. Phys Med Biol. 2006;51:1269–82. doi:10.1088/0031-9155/51/5/016.PubMedCrossRef

52.

Sun J, Xu J, Cairns NJ, Perlmutter JS, Mach RH. Dopamine D1, D2, D3 receptors, vesicular monoamine transporter type-2 (VMAT2) and dopamine transporter (DAT) densities in aged human brain. PLoS One. 2012;7:e49483. doi:10.1371/journal.pone.0049483.PubMedCentralPubMedCrossRef

53.

Staley JK, Krishnan-Sarin S, Zoghbi S, Tamagnan G, Fujita M, Seibyl JP, et al. Sex differences in [123I]beta-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse. 2001;41:275–84. doi:10.1002/syn.1084.PubMedCrossRef

54.

Lavalaye J, Booij J, Reneman L, Habraken JB, van Royen EA. Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med. 2000;27:867–9.PubMedCrossRef

55.

Amir S, Robinson B, Ratovitski T, Rea MA, Stewart J, Simantov R. A role for serotonin in the circadian system revealed by the distribution of serotonin transporter and light-induced Fos immunoreactivity in the suprachiasmatic nucleus and intergeniculate leaflet. Neuroscience. 1998;84:1059–73.PubMedCrossRef

56.

Buchert R, Schulze O, Wilke F, Berding G, Thomasius R, Petersen K, et al. Is correction for age necessary in SPECT or PET of the central serotonin transporter in young, healthy adults? J Nucl Med. 2006;47:38–42.PubMed

57.

Sanchez MG, Morissette M, Di Paolo T. Oestradiol modulation of serotonin reuptake transporter and serotonin metabolism in the brain of monkeys. J Neuroendocrinol. 2013;25:560–9. doi:10.1111/jne.12034.PubMedCrossRef

58.

Volkow ND, Fowler JS, Wang GJ, Logan J, Schlyer D, MacGregor R, et al. Decreased dopamine transporters with age in healthy human subjects. Ann Neurol. 1994;36:237–9.PubMedCrossRef

59.

De Keyser J, Ebinger G, Vauquelin G. Age-related changes in the human nigrostriatal dopaminergic system. Ann Neurol. 1990;27:157–61.PubMedCrossRef

60.

Mozley PD, Acton PD, Barraclough ED, Plossl K, Gur RC, Alavi A, et al. Effects of age on dopamine transporters in healthy humans. J Nucl Med. 1999;40:1812–7.PubMed

61.

Schwarz J, Storch A, Koch W, Pogarell O, Radau PE, Tatsch K. Loss of dopamine transporter binding in Parkinson's disease follows a single exponential rather than linear decline. J Nucl Med. 2004;45:1694–7.PubMed

62.

Bannon MJ, Whitty CJ. Age-related and regional differences in dopamine transporter mRNA expression in human midbrain. Neurology. 1997;48:969–77.PubMedCrossRef

63.

Booij J, de Win MM. Brain kinetics of the new selective serotonin transporter tracer [123I]ADAM in healthy young adults. Nucl Med Biol. 2006;33:185–91. doi:10.1016/j.nucmedbio.2005.10.005.PubMedCrossRef

64.

Lee NJ, Park IS, Koh I, Jung TW, Rhyu IJ. No volume difference of medulla oblongata between young and old Korean people. Brain Res. 2009;1276:77–82. doi:10.1016/j.brainres.2009.04.027.PubMedCrossRef

65.

Raz N, Gunning-Dixon F, Head D, Williamson A, Acker JD. Age and sex differences in the cerebellum and the ventral pons: a prospective MR study of healthy adults. AJNR Am J Neuroradiol. 2001;22:1161–7.PubMed

66.

Shioe K, Ichimiya T, Suhara T, Takano A, Sudo Y, Yasuno F, et al. No association between genotype of the promoter region of serotonin transporter gene and serotonin transporter binding in human brain measured by PET. Synapse. 2003;48:184–8. doi:10.1002/syn.10204.PubMedCrossRef

67.

Laruelle M, Vanisberg MA, Maloteaux JM. Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites. Biol Psychiatry. 1988;24:299–309.PubMedCrossRef

Title: Extrastriatal binding of [123I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls
Authors: Walter Koch
Marcus Unterrainer
Guoming Xiong
Peter Bartenstein
Markus Diemling
Andrea Varrone
John C. Dickson
Livia Tossici-Bolt
Terez Sera
Susanne Asenbaum
Jan Booij
Ozlem L. Kapucu
Andreas Kluge
Morten Ziebell
Jacques Darcourt
Flavio Nobili
Marco Pagani
Swen Hesse
Thierry Vander Borght
Koen Van Laere
Klaus Tatsch
Christian la Fougère
Publication date: 01-10-2014
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 10/2014
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-014-2785-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Extrastriatal binding of [¹²³I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2014

Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)

18F-fluorodeoxyglucose positron emission tomography combined with whole-body computed tomographic angiography in critically ill patients with suspected severe sepsis with no definite diagnosis

The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy

Erratum to: Value of 18 F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma

Correlation between 18F-fluoromisonidazole PET and expression of HIF-1α and VEGF in newly diagnosed and recurrent malignant gliomas

11C-ORM-13070, a novel PET ligand for brain α2C-adrenoceptors: radiometabolism, plasma pharmacokinetics, whole-body distribution and radiation dosimetry in healthy men